Check out Jim Cramer's latest trading recommendations on "Action Alerts Plus". (Updates from 10:47 a.m. ET with closing information.)
NEW YORK (TheStreet) -- Here's what Jim Cramer had to say on CNBC's "Squawk on the Street" Tuesday.
Everyone hated Allergan (AGN - Get Report) a few months ago, Cramer said. But because its new drug, Restasis, has no patent infringements and is projected to do well, investors like it again. RBC Capital Markets recommended it as a buy. AGN rose 1.6% to $112.55.
Goldman Sachs downgraded Alliance Data Systems (ADS - Get Report) to hold from buy. Cramer disagreed, saying its business is doing great. Goldman Sachs is saying "it's too expensive. I think they're wrong," he said. ADS fell 1.2% to $255.19.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts